Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Aparici, M. Gómez-Angelats, D. Vilella, J. Cortijo, E. Morcillo, C. Carcasona, A. Gavaldà, J. Beleta, C. Puig, H. Ryder, M. Miralpeix (Barcelona, València, Spain). LAS100977 is a novel, potent β₂-agonist with rapid onset and sustained duration of action in vitro. Eur Respir J 2010; 36: Suppl. 54, 1182

Member's Comments

No comment yet.

Related content which might interest you: Indacaterol, a novel 24-hour β2-agonist, demonstrates a long duration of action and fast onset in vitro and in vivo in the guinea pig Source: Eur Respir J 2005; 26: Suppl. 49, 122s Year: 2005 AZD3199: A potent and selective β2-adrenergic receptor agonist with rapid onset of action Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011 LAS100977, a novel β2-agonist, has a longer duration of action and a more favourable therapeutic index than salmeterol in anaesthetised dogs Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 AZD3199: A fast acting β2-receptor agonist with a long duration of action Source: Annual Congress 2011 - Translational models of disease Year: 2011 In vitro pharmacological profile of SMP-028, a novel potent anti-inflammatory agent Source: Annual Congress 2010 - Models of airways disease Year: 2010 The in vitro biology of Compound X – a novel β2 adrenoceptor agonist with a long duration of action Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 Duration and onset of action of indacaterol, a novel 24-hour β2-agonist, on isolated human bronchus Source: Eur Respir J 2005; 26: Suppl. 49, 216s Year: 2005 NIK-616, a new type of selective phosphodiesteraseIV(PDE IV) inhibitor with reduced emetic activity Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 Safety profile of a novel peptide,PIN201104,with potential to act as a disease modifying,broad spectrum treatment for asthma Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018 Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002 Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity Source: Eur Respir J, 59 (3) 2004306; 10.1183/13993003.04306-2020 Year: 2022 In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 The in vitro biology of PF-00610355 – a novel β2 adrenoceptor agonist with a long duration of action Source: Annual Congress 2009 - Models of chronic airways disease and therapy Year: 2009 Dual mechanism of action of T2 inhibitor therapies in virally induced exacerbations of asthma: evidence for a beneficial counter-regulation Source: Eur Respir J, 54 (1) 1802390; 10.1183/13993003.02390-2018 Year: 2019 Pharmacological profile of a novel, potent and oral TRPA1 antagonist. Characterization in a preclinical model of induced cough Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 The inhaled anticholinergic agent, aclidinium bromide, reverses cholinergic-induced bronchoconstriction in guinea pigs with a fast onset of action and a long duration of effect Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008 In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systems Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 The effect of pain conditioning on experimentally evoked cough: evidence of impaired endogenous inhibitory control mechanisms in refractory chronic cough Source: Eur Respir J, 56 (6) 2001387; 10.1183/13993003.01387-2020 Year: 2020 Late-breaking abstract: Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease Year: 2011